Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Contact 844-434-4210
Participate-In-This-Study1@its.jnj.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Back

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Recruiting

Open to: ALL

Age: 18.0 - N/A

Leeds Manchester Newcastle Stoke on Trent Barnet Bradford Coventry

Medical Conditions

Arthritis
Arthritis, Psoriatic

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2021 Mar 2026

Publications

"Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Ostergaard M, Baraliakos X. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y."; "36064592"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Guselkumab will be administered as subcutaneous injection.

Intervention Arm Group : Group 1: Guselkumab and Placebo;Group 2: Guselkumab;Group 3: Placebo followed by Guselkumab;

Intervention Type : DRUG
Intervention Description : Matching placebo will be administered as subcutaneous injection.

Intervention Arm Group : Group 1: Guselkumab and Placebo;Group 3: Placebo followed by Guselkumab;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Chapel Allerton Hospital
    Leeds
    LS7 4SA
  • Central Manchester University Hospitals NHS Foundation Trust
    Manchester
    M13 9WL
  • North Tyneside General Hospital
    Newcastle
    NE29 8NH
  • Haywood Hospital
    Stoke on Trent
    ST6 7AG
  • Royal Free London NHS Foundation Trust
    Barnet
    EN5 3DJ
  • St. Lukes Hospital
    Bradford
    BD5 0NA
  • University Hospital Coventry & Warwickshire NHS Trust
    Coventry
    CV2 2DX

Study Contact 844-434-4210
Participate-In-This-Study1@its.jnj.com



The study is sponsored by Janssen Research & Development, LLC




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04929210
Last updated 22 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top